These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38279418)

  • 1. Bcl-2 expression in cell lines breast cancer and death program.
    Janaghard MS; Soleimani S; Movafagh A; Motallebi M; Mousavi SA; Moghadam AAS; Moghadam VE; Khosravi A; Mirzaei HR; Mousavi SAR; Aziziaram Z; Sun C
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):277-285. PubMed ID: 38279418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
    Chi KC; Wallis AE; Lee CH; De Menezes DL; Sartor J; Dragowska WH; Mayer LD
    Breast Cancer Res Treat; 2000 Oct; 63(3):199-212. PubMed ID: 11110054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of antisense oligonucleotides bcl-2/bcl-xl and bcl-2 on proliferation and apoptosis of breast cancer cells].
    Ma C; Xie JW; Kuang AR; Huang R; Tang GS
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):780-3. PubMed ID: 19950582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
    Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
    Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
    Simões-Wüst AP; Olie RA; Gautschi O; Leech SH; Häner R; Hall J; Fabbro D; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2000 Aug; 87(4):582-90. PubMed ID: 10918201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.
    Nahta R; Yuan LX; Fiterman DJ; Zhang L; Symmans WF; Ueno NT; Esteva FJ
    Mol Cancer Ther; 2006 Jun; 5(6):1593-601. PubMed ID: 16818519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?
    Lilling G; Hacohen H; Nordenberg J; Livnat T; Rotter V; Sidi Y
    Cancer Lett; 2000 Dec; 161(1):27-34. PubMed ID: 11078910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations.
    Meidan VM; Glezer J; Salomon S; Sidi Y; Barenholz Y; Cohen JS; Lilling G
    J Liposome Res; 2006; 16(1):27-43. PubMed ID: 16556548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
    Jiang H; Xia D; Wu LJ; Chen ZD
    Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Cancer; 2005 May; 103(10):2199-207. PubMed ID: 15830342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.
    Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
    Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Albritton KH; Bastar JD; Randall RL
    J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy.
    Chen T; Xu J; Zhu L; Yan D
    Nanoscale; 2023 Jan; 15(4):1914-1924. PubMed ID: 36617999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide.
    Yang JH; Feng F; Qian H; Cheng H
    Breast; 2004 Jun; 13(3):227-31. PubMed ID: 15177426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
    Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.